[1]Patent:CN107353291,2017,A.Locationinpatent:Paragraph0068;0069;0070
[2]Patent:US2018/44339,2018,A1.Locationinpatent:Paragraph0113;0114
[3]Patent:CN108623606,2018,A.Locationinpatent:Paragraph0048
[4]Patent:US2017/145017,2017,A1.Locationinpatent:Paragraph0127;0128;0133
[5]Patent:CN106188062,2016,A.Locationinpatent:Paragraph0088;0089;0090;0091;0092;0093
[6]Patent:CN108623602,2018,A.Locationinpatent:Paragraph0022;0023;0025
[7]Patent:CN107383017,2017,A.Locationinpatent:Paragraph0016;0038;0039;0040;00410042;0043
[8]JournalofMedicinalChemistry,2015,vol.58,p.9625-9638
[9]Patent:WO2014/176348,2014,A1.Locationinpatent:Page/Pagecolumn66;67
[10]OrganicandBiomolecularChemistry,2015,vol.13,p.5147-5157
[11]Patent:CN105622613,2016,A.Locationinpatent:Paragraph0109;0208;0209;0210;0211;0212;0213-0218
[12]Patent:WO2017/137446,2017,A1.Locationinpatent:Page/Pagecolumn16
[13]Patent:WO2017/163257,2017,A1.Locationinpatent:Page/Pagecolumn19
[14]Patent:CN107286163,2017,A.Locationinpatent:Paragraph0120;0121
[1]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2016/50422,2016,A1Locationinpatent:Page/Pagecolumn13-14
[1]CurrentPatentAssignee:ADVENTINTERNATIONALCORPORATION-WO2016/127960,2016,A1Locationinpatent:Page/Pagecolumn7
[2]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2016/50422,2016,A1Locationinpatent:Page/Pagecolumn16
[1]CurrentPatentAssignee:SINOBIOPHARMACEUTICALLIMITED;SHANGHAIDUDEMEDICALSCIENCEANDTECHNOLOGYCOLTD-US2018/44339,2018,A1Locationinpatent:Paragraph0091;0092
[2]CurrentPatentAssignee:SUNPHARMACEUTICALINDUSTRIESLIMITED-WO2016/79693,2016,A1Locationinpatent:Page/Pagecolumn29
[1]Patent:CN105859728,2016,A.Locationinpatent:Paragraph0056;0057;0058;0068;0069
[2]Patent:CN104557945,2017,B.Locationinpatent:Paragraph0077;0079;0081;0082;0083;0084;0085;0086
[3]Patent:CN107641123,2018,A.Locationinpatent:Paragraph0014;0020
[4]Patent:WO2017/134588,2017,A1.Locationinpatent:Page/Pagecolumn17
Title: Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes.
Journal: Toxicology letters 20180701
Title: Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma.
Journal: Journal of cancer research and clinical oncology 20180401
Title: Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Journal: Expert opinion on investigational drugs 20180101
Title: The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein.
Journal: The Journal of biological chemistry 20161014
Title: Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Journal: Oncotarget 20160906
Title: Mantle Cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20160410
Title: Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Journal: The New England journal of medicine 20160128
Title: Label-Free Bottom-Up Proteomic Workflow for Simultaneously Assessing the Target Specificity of Covalent Drug Candidates and Their Off-Target Reactivity to Selected Proteins.
Journal: Chemical research in toxicology 20160119
Title: Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas.
Journal: Leukemia 20160101
Title: Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
Journal: Blood 20150924
Title: Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
Journal: Drugs 20150501
Title: Ibrutinib in pretreated Waldenström's macroglobulinaemia.
Journal: The Lancet. Oncology 20150501
Title: Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
Journal: Leukemia 20150401
Title: Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20150201
Title: Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.
Journal: Proceedings of the National Academy of Sciences of the United States of America 20140805
Title: Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.
Journal: Journal of medicinal chemistry 20140626
Title: Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).
Journal: Leukemia & lymphoma 20131101
Title: Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia.
Journal: Leukemia & lymphoma 20130801
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
Journal: The New England journal of medicine 20130704
Title: Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.
Journal: Expert review of clinical immunology 20130601
Title: Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials.
Journal: Current hematologic malignancy reports 20130301
Title: Ibrutinib and novel BTK inhibitors in clinical development.
Journal: Journal of hematology & oncology 20130101
Title: Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.
Journal: Cancer journal (Sudbury, Mass.) 20120901
Title: Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
Journal: Blood 20120830
Title: Irreversible protein kinase inhibitors: balancing the benefits and risks.
Journal: Journal of medicinal chemistry 20120726
Title: Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.
Journal: Cancer cell 20120612
Title: Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies.
Journal: Journal of medicinal chemistry 20120524
Title: The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
Journal: Blood 20120315
Title: Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.
Journal: Current hematologic malignancy reports 20120301
Title: Novel targeted therapies for mantle cell lymphoma.
Journal: Oncotarget 20120201
Title: Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.
Journal: Bioorganic & medicinal chemistry letters 20111101
Title: Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma.
Journal: Neoplasia (New York, N.Y.) 20111101
Title: Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Journal: Blood 20110609
Title: Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor.
Journal: International immunopharmacology 20110401
Title: The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.
Journal: Arthritis research & therapy 20110101
Title: More than just B-cell inhibition.
Journal: Arthritis research & therapy 20110101
Title: Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.
Journal: ChemMedChem 20070101
Title: Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80.
Title: Herman SE, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011 Jun 9;117(23):6287-96.
Title: Chang BY, et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther. 2011 Jul 13;13(4):R115.
Title: Sun Y, et al. PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. Cell Res. 2018 Jul;28(7):779-781.